The augment of regulatory T cells undermines the efficacy of anti-PD-L1 treatment in cervical cancer

Abstract

Anti-PD-L1 treatment upregulates Tregs frequency and proliferation in tumor model, and the depletion of Tregs may be a useful adjuvant strategy for anti-PD-L1 therapy of cervical cancer.